Skip to main navigation Skip to search Skip to main content

KATP channels are necessary for glucose-dependent increases in amyloid-β and Alzheimer’s disease–related pathology

  • John Grizzanti
  • , William R. Moritz
  • , Morgan C. Pait
  • , Molly Stanley
  • , Sarah D. Kaye
  • , Caitlin M. Carroll
  • , Nicholas J. Constantino
  • , Lily J. Deitelzweig
  • , James A. Snipes
  • , Derek Kellar
  • , Emily E. Caesar
  • , Ryan J. Pettit-Mee
  • , Stephen M. Day
  • , Jonathon P. Sens
  • , Noelle I. Nicol
  • , Jasmeen Dhillon
  • , Maria S. Remedi
  • , Drew D. Kiraly
  • , Celeste M. Karch
  • , Colin G. Nichols
  • David M. Holtzman, Shannon L. Macauley

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Elevated blood glucose levels, or hyperglycemia, can increase brain excitability and amyloid-β (Aβ) release, offering a mechanistic link between type 2 diabetes and Alzheimer’s disease (AD). Since the cellular mechanisms governing this relationship are poorly understood, we explored whether ATP-sensitive potassium (KATP) channels, which couple changes in energy availability with cellular excitability, play a role in AD pathogenesis. First, we demonstrate that KATP channel subunits Kir6.2/KCNJ11 and SUR1/ABCC8 were expressed on excitatory and inhibitory neurons in the human brain, and cortical expression of KCNJ11 and ABCC8 changed with AD pathology in humans and mice. Next, we explored whether eliminating neuronal KATP channel activity uncoupled the relationship between metabolism, excitability, and Aβ pathology in a potentially novel mouse model of cerebral amyloidosis and neuronal KATP channel ablation (i.e., amyloid precursor protein [APP]/PS1 Kir6.2–/–mouse). Using both acute and chronic paradigms, we demonstrate that Kir6.2-KATP channels are metabolic sensors that regulate hyperglycemia-dependent increases in interstitial fluid levels of Aβ, amyloidogenic processing of APP, and amyloid plaque formation, which may be dependent on lactate release. These studies identify a potentially new role for Kir6.2-KATP channels in AD and suggest that pharmacological manipulation of Kir6.2-KATP channels holds therapeutic promise in reducing Aβ pathology in patients with diabetes or prediabetes.

Original languageEnglish
Article numbere162454
JournalJCI insight
Volume8
Issue number10
DOIs
StatePublished - May 22 2023

Bibliographical note

Publisher Copyright:
© 2023, Grizzanti et al.

Funding

We would like to acknowledge the following grants: NIH 1K01AG050719 (to SLM), R01AG068330 (to SLM), BrightFocus Foundation (A20201775S; to SLM), Charleston Conference on Alzheimer’s Disease New Vision Award (SLM), Averill Foundation (to SLM), and NIH P01NS080675 (to DMH and SLM), R35HL140024 (to CGN), F31AG066302 (to CMC), T32AG033534 (to JG), T32AA007565 (to SMD), and F31AG071119 (to MP).

FundersFunder number
Averill FoundationR35HL140024, P01NS080675, F31AG066302
National Institutes of Health (NIH)1K01AG050719, R01AG068330
BrightFocus FoundationA20201775S
Catholic Medical CenterT32AG033534, T32AA007565, F31AG071119

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    ASJC Scopus subject areas

    • General Medicine

    Fingerprint

    Dive into the research topics of 'KATP channels are necessary for glucose-dependent increases in amyloid-β and Alzheimer’s disease–related pathology'. Together they form a unique fingerprint.

    Cite this